Ipamorelin (5mg / 10mg) appears in Growth Research catalogs for qualified buyers who need specification, COA, and RUO clarity—Ipamorelin Specification and Vial Format Review summarizes key checks.
Ipamorelin is a synthetic pentapeptide used in laboratory research on ghrelin-receptor pathway signaling, growth-axis models, receptor selectivity, and peptide structure-activity studies.
Ipamorelin selectively activates the ghrelin receptor (GHS-R1a) without significant cortisol or prolactin co-release in published pituitary cell models. Hexapeptide structure confers receptor selectivity compared with earlier growth-hormone secretagogue peptides affecting multiple pathways.
GH pulse amplitude measurements in conscious rat microdialysis models and GHS-R1a cAMP assays validate selective secretagogue activity. Ipamorelin pharmacology papers from Novo Nordisk research groups established selectivity profiles using pituitary cell panels.
Side-by-side review of specification table, vial label, and COA prevents release errors for Ipamorelin. Principal investigators should sign off Ipamorelin SKUs only after mechanism fit is documented in the study protocol.
Spec alignment: Enter exact strength notation (5mg / 10mg) in procurement systems—do not round kit counts.
Catalog identifiers for Ipamorelin: CAS 170851-70-4, Formula: C38H49N9O5. MW 711.85 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Publication methods should list Cat No. and mg strength for Ipamorelin to support reproducibility.
Dose planning for Ipamorelin should state mass (5mg / 10mg) or molarity derived from catalog molecular weight.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for Ipamorelin. QA sign-off should reference all four documents in the batch record. Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for Ipamorelin should state whether the lot COA must meet or exceed that threshold for your Growth Research assay type.
Specification alignment for Ipamorelin requires copying exact kit notation (5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits. Molecular identifiers for Ipamorelin—CAS 170851-70-4, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing Ipamorelin should include these fields for reproducibility in Growth Research journals.
Format selection for Ipamorelin affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
Molecular identifiers for Ipamorelin—CAS 170851-70-4, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing Ipamorelin should include these fields for reproducibility in Growth Research journals. Format selection for Ipamorelin affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
Specification alignment for Ipamorelin requires copying exact kit notation (5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Format selection for Ipamorelin affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability. Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for Ipamorelin. QA sign-off should reference all four documents in the batch record.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for Ipamorelin should state whether the lot COA must meet or exceed that threshold for your Growth Research assay type. Specification alignment for Ipamorelin requires copying exact kit notation (5mg / 10mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Molecular identifiers for Ipamorelin—CAS 170851-70-4, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing Ipamorelin should include these fields for reproducibility in Growth Research journals.
Ipamorelin from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.